Fig. 5.

IFNγ production increases upon the addition of pAc/emm55 vector and anti-PD-1 therapy. Murine melanoma B16 cells were injected subcutaneously on day 0. pEmpty vector or pEmm55 vector was injected on days 7, 14, and 21. Starting on day 8, mice received intraperitoneal injection of either isotype control antibody or anti-PD-1 blocking antibody (250 μg/200μL/IP) twice weekly (a). b Splenocytes collected from mice treated with emm55 vector ± anti-PD-1 therapy were co-cultured with B16 melanoma cells, and culture supernatants were collected after 24 h. Levels of IFNγ were measured (p < 0.01 utilizing unpaired T test with Bonferroni correction). c Tumor sizes for these B16 tumors at day 25 were also measured and demonstrated an increased response with pEmm55/anti-PD-1 compared to anti-PD-1 therapy alone (p < 0.05; unpaired T test). d Tumor growth curves from each treatment group. (N = 12 for treatment groups, N = 9 for control pEmpty group). *p < 0.05